Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure

Journal of the American College of Cardiology

Volumn 35, Issue 1, 2000, Pages 222-229

  Mishima, Takayuki ^b   Tanimura, Mitsuhiro ^b   Suzuki, George ^b   Todor, Anastassia ^b   Sharov, Victor G ^b   Goldstein, Sidney ^b   Sabbah, Hani N ^a,b  

^a Henry Ford Heart and Vascular Institute ^*

^b HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOG; DRUG EFFECT; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HYPERTROPHY; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; DOGS; HEART FAILURE, CONGESTIVE; INFUSIONS, INTRAVENOUS; MYOCARDIUM; STROKE VOLUME; SULFONAMIDES; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 0033955134     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00528-8     Document Type: Article

References (51)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
2. Miller W, Redfield M, Burnett JC Jr. Integrated cardiac, renal and endocrine actions of endothelin. J Clin Invest 1989;83:3107-20.
3. Rubanyi GM, Parker Botelho LH. Endothelins. FASEB J 1991;5:2713-20.
4. Krämer BK, Nishida M, Kelly RA, Smith TW. Endothelins. Circulation 1992;85:350-6.
5. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994;89:1580-6.
6. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-9.
7. Cavero PG, Miller WL, Heublein DM, et al. Endothelin in experimental congestive heart failure in the anesthetized dog. Am J Physiol 1990;259:F312-7.
8. Margulies KB, Hildebrand FL Jr., Lerman A, et al. Increased endothelin in experimental heart failure. Circulation 1990;82:2226-30.
9. Kiowski W, Lüscher TF, Linder L, Bühler FR. Endothelin-1-induced vasoconstriction in humans. Circulation 1991;83:469-75.
10. Kiowski W, Sütsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-6.
11. Krämer BK, Smith TW, Kelly RA. Endothehn and increased contractility in adult rat ventricular myocytes. Circ Res 1991;68:269-79.
12. Hattori Y, Nakaya H, Nishihira J, Kanno M. A dual-component positive inotropic effect of endothelin-1 in guinea pig left atria: a role of protein kinase C. J Pharmacol Exp Ther 1993;266:1202-12.
13. Kasai H, Takanashi M, Takasaki C, Endoh M. Pharmacological properties of endothelin receptor subtypes mediating positive inotropic effects in rabbit heart. Am J Physiol 1994;266:H2220-8.
14. McClellan G, Weisberg A, Winegrad S. Endothelin regulation of cardiac contractility in absence of added endothelin. Am J Physiol 1995;268:H1621-7.
15. Ito H, Hirata Y, Hiroe M, et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991;69:209-15.
16. A receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 1994;89:2198-203.
17. Harada M, Ito H, Nakagawa O, et al. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy. Circulation 1997;96:3737-44.
18. Guarda E, Katwa LC, Myers PR, et al. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993;27:2130-4.
19. B receptor antagonist, bosentan, on endothelin-1-induced myocardial ischaemia and oedema in the rat. Br J Pharmacol 1995;116:1745-50.
20. Omland T, Lie RT, Aakvaag A, et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994;89:1573-9.
21. Kiowski W, Sütsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-6.
22. Shimoyama H, Sabbah HN, Borzak S, et al. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation 1996;94:779-84.
23. Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure. Circulation 1997;96:1976-82.
24. Sakai S, Miyauchi T, Sakurai T, et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Circulation 1996;93:1214-22.
25. Sakai S, Miyauchi T, Kobayashi M, et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996;384:353-5.
26. Spinale FG, Walker JD, Mukherjee R, et al. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Circulation 1997;95:1918-29.
27. Yazaki Y, Yamazaki T. Reversing congestive heart failure with endothelin receptor antagonists. Circulation 1997;95:1752-4.
28. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-35.
29. Sütsch G, Bertel O, Kiowski W. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drug Ther 1996;10:717-25.
30. Sütsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998;98:2262-8.
31. Sabbah HN, Stein PD, Kono T, et al. A canine model of chronic heart failure produced by multiple sequential intracoronary microembolizations. Am J Physiol 1991;260:H1379-84.
32. Sabbah HN, Shimoyama H, Kono T, et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-9.
33. Dodge HT, Sandler H, Baxley WA, Hawley RR. Usefulness and limitations of radiographic methods for determining left ventricular volume. Am J Cardiol 1966;18:10-24.
34. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensm-II type-1 receptor antagonists in rats with heart failure. J Clin Invest 1997;99:1926-35.
35. Iwanaga Y, Kihara Y, Hasegawa K, et al. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation 1998;98:2065-73.
36. Faccarollo D, Hu K, Galuppo P, et al. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction. Circulation 1997;96:3963-73.
37. A receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996;94:2131-7.
38. Ito H, Hirata Y, Adachi S, et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993;92:398-403.
39. Boarder MR, Marriott DB. Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells. J Cardiovasc Pharmacol 1989;13 Suppl 5:S223-4.
40. Kaddoura S, Firth JD, Boheler KR, et al. Endothelin-1 involved in norepinephrine-induced ventricular hypertrophy in vivo. Circulation 1996;93:2068-79.
41. Nguyen QT, Cernacek P, Calderoni A, et al. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 1998;98:2323-30.
42. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensm-aldosterone system. Circulation 1991;83:1849-65.
43. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension. Cardiovasc Res 1992;26:671-7.
44. Sabbah HN, Sharov VG, Lesch M, Goldstein S. Progression of heart failure: a role for interstitial fibrosis. Mol Cell Biochem 1995;147:29-34.
45. Weber KT, Anversa P, Armstrong PW, et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992;20:3-16.
46. Ebhbali-Webb M. Cardiac fibroblasts. In: Eghbali-Webb M, editor. Molecular Biology of the Collagen Matrix in the Heart. Austin (TX): R.G. Landes Company, 1995:24-40.
47. 2+ modulation. Circ Res 1996;78:302-11.
48. Ono K, Tsujimoto G, Sakamoto A, et al. Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature 1994;370:301-4.
49. Jones LG. Inhibition of cAMP accumulation by endothelin is pertussis toxin sensitive and calcium independent in isolated adult feline cardiac myocytes. Life Sci 1996;58:115-23.
50. 2+ -ATPase gene expression and calcium reuptake. J Mol Cell Cardiol 1996;28:2467-77.
51. Prasad MR. Endothelin stimulates degradation of phosphohpids in isolated rat hearts. Biochem Biophys Res Commun 1991;174:952-7.